NewCo News: Cyrenaic Targets Untreated Schizophrenia Symptoms
By Marie Powers
Wednesday, March 16, 2011
Cyrenaic Pharmaceuticals Inc. is a little company with big dreams. The privately held biotech, based in Princeton, N.J., is focused on the development of CYR-101, an antipsychotic in clinical development for the treatment of schizophrenia.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.